PKM and glioblastoma: The survival durations for the 76 GBM patients, all of whom received standard adjuvant radiotherapy after surgery, followed by treatment with an alkylating agent (temozolomide in the majority of cases), were compared between the patients with low PKM2 pS222 (0–4.9 staining) and the patients with high PKM2 pS222 (5–8 staining).